title: Pulmonary hypertension associated with myeloproliferative disorders: a retrospective study of ten cases.
abstract: BACKGROUND
  Pulmonary hypertension (PH) is a severe hemodynamic disorder in which the pulmonary artery pressure is persistently elevated, leading to right-sided heart failure. Some studies have suggested an association between PH and myeloproliferative diseases (MPD).
  
  
  OBJECTIVE
  This study describes clinical, hematological and hemodynamic characteristics of PH associated with MPD.
  
  
  METHODS
  We retrospectively reviewed 10 cases of PH associated with MPD: polycythemia vera (8 patients) and essential thrombocythemia (2 patients), followed between 1993 and 2002. The baseline evaluation was established by right-sided heart catheterization, ventilation/perfusion lung scan and pulmonary angiography if required.
  
  
  RESULTS
  Six patients had confirmed chronic thromboembolic pulmonary hypertension (CTEPH) and 4 had pulmonary arterial hypertension (PAH) associated with MPD without other risk factors for PAH. The hemodynamic characteristics of CTEPH and PAH associated with MPD were similar. The diagnosis of CTEPH was concomitant to that of MPD in all cases (5 polycythemia vera and 1 essential thrombocythemia). The PAH associated with MPD occurred later in the evolution of the MPD (3 polycythemia vera and 1 essential thrombocythemia) with a median of 162 months after the diagnosis of MPD, and it was associated with myeloid metaplasia (p < 0.01).
  
  
  CONCLUSIONS
  We describe 2 distinct forms of PH in the context of MPD: CTEPH, which is diagnosed at an early stage of the MPD, and PAH, which occurs later in the course of the MPD and is associated with myeloid metaplasia. Progressively increasing dyspnea in a patient with an MPD warrants further investigation to rule out PAH and CTEPH, while a diagnosis of CTEPH warrants ruling out MPD.
authors.affiliation: Department of Clinical Hematology, Hôpital Necker-Enfants-Malades, Assistance Publique - Hôpitaux de Paris, Université Paris-V, Paris, France.
authors.forename: P
authors.initials: P
authors.lastname: Guilpain
authors.forename: D
authors.initials: D
authors.lastname: Montani
authors.forename: G
authors.initials: G
authors.lastname: Damaj
authors.forename: L
authors.initials: L
authors.lastname: Achouh
authors.forename: F
authors.initials: F
authors.lastname: Lefrère
authors.forename: J
authors.initials: J
authors.lastname: Le Pavec
authors.forename: A
authors.initials: A
authors.lastname: Marfaing-Koka
authors.forename: P
authors.initials: P
authors.lastname: Dartevelle
authors.forename: G
authors.initials: G
authors.lastname: Simonneau
authors.forename: M
authors.initials: M
authors.lastname: Humbert
authors.forename: O
authors.initials: O
authors.lastname: Hermine
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000150:complications* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011087:Polycythemia Vera / Q000150:complications* / Q000628:therapy; D055728:Primary Myelofibrosis / Q000150:complications; D011652:Pulmonary Circulation; D011655:Pulmonary Embolism / Q000150:complications* / Q000628:therapy; D012189:Retrospective Studies; D013920:Thrombocythemia, Essential / Q000150:complications* / Q000628:therapy